All In Biotech

Drug Trial Radar · NCT03259867

Combination of TATE and PD-1 Inhibitor in Liver Cancer

Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody

Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Jul 1, 2017

Primary completion

Dec 30, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Teclison Ltd.Industry
Sponsor type
Industry
First posted
Aug 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.

Conditions

  • Hepatocellular Carcinoma
  • Gastric Cancer

Interventions

  • Nivolumab Injectable ProductDrug

    a PD-1 immune check inhibitor

  • Trans-arterial tirapazamine embolizationCombination product

    Embolization with Lipiodol and Gelfoam

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: up to 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine

    Orange, California · Recruiting

  • University of Oklahoma Health Science Center

    Oklahoma City, Oklahoma · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.